• HOME

  • ABOUT

  • FACULTY

  • PROSPECTUS

    • 2021 PROSPECTUS
  • SPONSORS

  • CONTACT

  • More

    Use tab to navigate through the menu items.

    HCC NEWS & LIBRARY

    ARTICLES:

    FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma

    FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer

    Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

    Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer

    Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-Free Survival in People With Unresectable Hepatocellular Carcinoma

    © 2021 by Focus Medical Communications, Inc.